Gabapentin (GBP)(C9H17NO2), with the trade name Neurontin, is a new antiepileptic drug
that was introduced by Park Davis Company in 1993 for adjunctive therapy of partial and …

OBJECTIVE: To evaluate the effects of gabapentin (GBP) administration on mice fetuses.
METHODS: This study was carried out in Birjand University of Medical Sciences during …

Purpose: To study the anticonvulsant effects of gabapentin (GBP) in immature animals.
Methods: Motor seizures were induced by pentylenetetrazol in 7‐, 12‐, 18‐, 25‐day‐old, and …

For therapeutic management of epileptic seizures in adults, second-generation antiepileptic
drugs (AEDs) are better option than classical AEDs considering their safety concerns …

Introduction: We aim to study and elucidate the safety profile of the antiepileptic doses of
gabapentin during pregnancy, and to evaluate gabapentin-induced murine fetotoxicity at …

Gabapentin (GBP, Neurontin), a new antiepi‐leptic drug (AED) with a novel mechanism of
action, exhibits low acute toxicity in mice, rats, and monkeys, and is not teratogenic. GBP …

AIM: To determine whether using gabapentin (GBP), especially in the first maternal trimester,
would affect the neural tube development of embryos in an early stage chick embryo (ESCE) …

Purpose: To study the pharmacokinetics of gabapentin (GBP) during delivery, lactation, and
in the neonatal period. Methods: GBP concentrations in plasma and breast milk were …

Although the cellular mechanisms of pharmacological actions of gabapentin (Neurontin®)
remain incompletely described, several hypotheses have been proposed. It is possible that …

Gabapentin represents a significant advance in the management of epilepsy. To date, it
appears to be most useful as an add-on therapy for patients with partial seizures …